Hidroxocobalamina Basi (Hydroxocobalamin)

Hydroxocobalamin injectable solution is indicated for two primary therapeutic purposes, both of which rely on its role as an active form of vitamin B12.

• Treatment of documented vitamin B12 deficiency, including pernicious anemia and malabsorption syndromes.
• Management of neurological manifestations associated with cobalamin deficiency, such as peripheral neuropathy.
• Emergency therapy for acute cyanide poisoning, administered intravenously or intramuscularly as an antidote.
• Supportive care in patients undergoing dialysis or receiving medications that interfere with cobalamin metabolism.
• Pre‑operative correction of low B12 levels in patients scheduled for major surgery.

• Hydroxocobalamin acts as a cofactor for the enzymes methionine synthase and methylmalonyl‑CoA mutase, facilitating the conversion of homocysteine to methionine and the metabolism of odd‑chain fatty acids. In cyanide poisoning, the cobalt center binds cyanide ions to form cyanocobalamin, which is then eliminated renally, thereby reducing systemic cyanide levels. This dual activity restores normal cobalamin‑dependent metabolic pathways while simultaneously detoxifying cyanide.

Adverse reactions to intramuscular hydroxocobalamin are generally infrequent, but they can be categorized by frequency and severity.

Common

• Injection site pain, erythema, or swelling.
• Transient headache or dizziness.
• Mild nausea or gastrointestinal discomfort.
• Mild flushing or warmth sensation.
• Transient metallic taste.
• Mild increase in serum creatinine.

Serious

• Severe hypersensitivity reactions, including anaphylaxis.
• Acute hemolytic anemia in patients with G6PD deficiency.
• Hypertensive crisis or rapid increase in blood pressure.
• Renal impairment due to cyanocobalamin precipitation.
• Seizures in patients with pre‑existing neurological disorders.

When prescribing hydroxocobalamin, clinicians should consider several precautionary measures to ensure safe use and to identify patients who may require monitoring.

• Assess vitamin B12 status before initiating therapy in patients with suspected deficiency.
• Use caution in individuals with known hypersensitivity to cobalamin preparations.
• Monitor blood pressure during and after administration, especially in patients with cardiovascular disease.
• Evaluate renal function, as high doses may affect creatinine clearance.
• Avoid use in patients with G6PD deficiency without prior hematologic assessment.
• Consider potential interference with laboratory assays that measure serum cobalamin levels.
• Document the indication and route of administration in the medical record.

Hydroxocobalamin may interact with certain medications or diagnostic agents; awareness of these interactions helps prevent reduced efficacy or increased toxicity.

Avoid

• Concurrent use with nitrous oxide anesthesia, which can inactivate vitamin B12 and diminish therapeutic effect.
• Simultaneous administration of high‑dose methotrexate, as cobalamin may alter folate metabolism.

Use with caution

• Laboratory assays for serum cobalamin or methylmalonic acid may give falsely elevated results after hydroxocobalamin injection.
• Patients receiving anticoagulants should be monitored, as vitamin B12 can influence homocysteine levels and platelet function.
• Co‑administration with other cyanide‑binding agents should be coordinated to avoid overlapping toxicity management.